肺动脉高血压中DNA损伤信号的作用
Jolyane Meloche1, Aude Pflieger, Mylène Vaillancourt
1Department of Medicine, Laval University, Pulmonary Hypertension Research Group, IUCPQ Research Centre, Québec, Canada (J.M., A.P., M.V., F.P., C.G., A.C., S.B.-B., E.T., C.C., S.P., S.B.); and Vascular Biology Research Group, Department of Medicine, University of Alberta, Edmonton, Canada (R.P., S.Z., E.D.M.).
肺动脉高血压 (PAH) 涉及DNA损伤和炎症. 向多P-ribose) 聚合酶-1 (PARP-1) 在逆转PAH方面显示出前景,提供了一种新的治疗策略.
科学领域:
- 心血管生物学 心血管生物学
- 分子医学是分子医学.
- 细胞信号传输 细胞信号传输
背景情况:
- 肺动脉高血压 (PAH) 与慢性炎症和DNA损伤有关.
- PAH光滑肌细胞 (PASMCs) 呈现出一种促增殖的,抗亡的表型.
- 这种表型是由miR-204,NFAT和HIF-1α激活维持的.
研究的目的:
- 为了研究多聚ADP-ribose) 聚合酶-1 (PARP-1) 在PAH中的作用.
- 确定PARP-1激活是否有助于PAH-PASMCs的增殖表型.
- 评估PAH中PARP-1抑制的治疗潜力.
主要方法:
- 评估了人类PAH组织和细胞中的DNA损伤标志物 (53BP1,γ-H2AX) 和PARP-1表达/活性.
- 研究了瘤亡因子-α对健康PASMCs的影响.
- 通过PARP-1分析了miR-204,NFAT和HIF-1α的调节.
- 测量了PASMC的扩散和亡.
- 在PAH的实验性大鼠模型中测试了一种PARP抑制剂 (ABT-888).
主要成果:
- PAH组织和细胞显示DNA损伤增加和PARP-1激活.
- 炎症诱导DNA损伤和PARP-1激活在PASMCs.
- PARP-1的激活降低了miR-204的调节,激活了NFAT和HIF-1α,促进了增殖和抑制了亡.
- 在大鼠模型中,PARP-1抑制逆转了PAH.
结论:
- DNA损伤/PARP-1通路对于PAH发展至关重要.
- PARP-1 是一种新型的PAH治疗点.
- 抑制PARP-1显示出治疗PAH的显著转化潜力.
相关概念视频
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...


